医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q1 FY14 Results on July 30, 2013

2013年07月19日 PM09:55
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the First Quarter ended June 30, 2013 on Tuesday, July 30, 2013 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com.

Summary of Events

 
Event     Date and Time (IST)     Medium
Release of financial results     July 30th, after the Board Meeting    

Email, Media, Company website, Business Wire

Earnings Call     July 30th, 6.30 PM IST / 9:00 AM EDT    

Hosted by the Company
(Details below)

Webcast of Earnings Call     July 30th, 6.30 PM IST / 9.00 AM EDT through August 4th, 2013    

URL available on Company’s website,

www.drreddys.com

Transcripts of the Earnings call     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

       

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance.

 
Conference Dial-In Numbers
Primary Number:     +91 22 6629 0356
Secondary Number:     +91 22 3065 0136

The numbers listed above are universally accessible from all networks and all countries.

Local Access Number:    

6000 1221
Available in – Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada
Accessible from all major carriers except BSNL/MTNL.
3940 3977
Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune
Accessible from all carriers.

USA: 1 866 746 2133

International Toll Free Number:

UK: 0 808 101 1573

Singapore: 800 101 2045

     

Hong Kong: 800 964 448

 

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through August 4th, 2013. For play back dial in phone No: 022 3065 1212 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company’s website.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets.

For more information, log on to: www.drreddys.com

*EDT- Eastern Daylight Saving Time

CONTACT

Investor Relations:
Dr. Reddy’s Laboratories
Kedar
Upadhye, +91 40 66834297
kedaru@drreddys.com
or
Saunak
Savla, +91 40 49002135
saunaks@drreddys.com
or
Milan
Kalawadia (USA), +1 9082034931
mkalawadia@drreddys.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表